1h1d

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
==Overview==
==Overview==
-
Catechol-O-methyltransferase (COMT; E.C. 2.1.1.6) is a ubiquitous enzyme, in nature that plays an important role in the metabolism of catechol, neurotransmitters and xenobiotics. In particular, inactivation of drugs, such as L-3,4-dihydroxyphenylalanine (L-DOPA) via O-methylation is of, relevant pharmacological importance, because L-DOPA is currently the most, effective drug used in the treatment of Parkinson's disease. This, justified the interest in developing COMT inhibitors as potential adjuncts, to L-DOPA therapy. The kinetics of inhibition by BIA 3-335, (1-[3,4-dihydroxy-5-nitrophenyl]-3-(N-3'-trifluormethylphenyl)-piperazine-, 1-propanone dihydrochloride) were characterized using recombinant rat, soluble COMT. BIA 3-335 was found to act as a potent, reversible, tight-binding inhibitor of COMT with a K(i) of 6.0 +/- 1.6 nM and, displaying a competitive inhibition toward the substrate binding site and, uncompetitive inhibition toward the S-adenosyl-L-methionine (SAM) binding, site. The 2.0-A resolution crystal structure of COMT in complex with its, cosubstrate SAM and a novel inhibitor BIA 3-335 shows the atomic, interactions between the important residues at the active site and the, inhibitor. This is the first report of a three-dimensional structure, determination of COMT complexed with a potent, reversible, and, tight-binding inhibitor that is expected to have therapeutic applications.
+
Catechol-O-methyltransferase (COMT; E.C. 2.1.1.6) is a ubiquitous enzyme in nature that plays an important role in the metabolism of catechol neurotransmitters and xenobiotics. In particular, inactivation of drugs such as L-3,4-dihydroxyphenylalanine (L-DOPA) via O-methylation is of relevant pharmacological importance, because L-DOPA is currently the most effective drug used in the treatment of Parkinson's disease. This justified the interest in developing COMT inhibitors as potential adjuncts to L-DOPA therapy. The kinetics of inhibition by BIA 3-335 (1-[3,4-dihydroxy-5-nitrophenyl]-3-(N-3'-trifluormethylphenyl)-piperazine- 1-propanone dihydrochloride) were characterized using recombinant rat soluble COMT. BIA 3-335 was found to act as a potent, reversible, tight-binding inhibitor of COMT with a K(i) of 6.0 +/- 1.6 nM and displaying a competitive inhibition toward the substrate binding site and uncompetitive inhibition toward the S-adenosyl-L-methionine (SAM) binding site. The 2.0-A resolution crystal structure of COMT in complex with its cosubstrate SAM and a novel inhibitor BIA 3-335 shows the atomic interactions between the important residues at the active site and the inhibitor. This is the first report of a three-dimensional structure determination of COMT complexed with a potent, reversible, and tight-binding inhibitor that is expected to have therapeutic applications.
==About this Structure==
==About this Structure==
Line 15: Line 15:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Archer, M.]]
[[Category: Archer, M.]]
-
[[Category: Bonifacio, M.J.]]
+
[[Category: Bonifacio, M J.]]
-
[[Category: Carrondo, M.A.]]
+
[[Category: Carrondo, M A.]]
-
[[Category: Learmonth, D.A.]]
+
[[Category: Learmonth, D A.]]
-
[[Category: Matias, P.M.]]
+
[[Category: Matias, P M.]]
-
[[Category: Rodrigues, M.L.]]
+
[[Category: Rodrigues, M L.]]
[[Category: Soares-Da-Silva, P.]]
[[Category: Soares-Da-Silva, P.]]
[[Category: BIA]]
[[Category: BIA]]
Line 27: Line 27:
[[Category: neurotransmitter degradation]]
[[Category: neurotransmitter degradation]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb 3 09:45:07 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 12:56:17 2008''

Revision as of 10:56, 21 February 2008


1h1d, resolution 2.0Å

Drag the structure with the mouse to rotate

CATECHOL O-METHYLTRANSFERASE

Overview

Catechol-O-methyltransferase (COMT; E.C. 2.1.1.6) is a ubiquitous enzyme in nature that plays an important role in the metabolism of catechol neurotransmitters and xenobiotics. In particular, inactivation of drugs such as L-3,4-dihydroxyphenylalanine (L-DOPA) via O-methylation is of relevant pharmacological importance, because L-DOPA is currently the most effective drug used in the treatment of Parkinson's disease. This justified the interest in developing COMT inhibitors as potential adjuncts to L-DOPA therapy. The kinetics of inhibition by BIA 3-335 (1-[3,4-dihydroxy-5-nitrophenyl]-3-(N-3'-trifluormethylphenyl)-piperazine- 1-propanone dihydrochloride) were characterized using recombinant rat soluble COMT. BIA 3-335 was found to act as a potent, reversible, tight-binding inhibitor of COMT with a K(i) of 6.0 +/- 1.6 nM and displaying a competitive inhibition toward the substrate binding site and uncompetitive inhibition toward the S-adenosyl-L-methionine (SAM) binding site. The 2.0-A resolution crystal structure of COMT in complex with its cosubstrate SAM and a novel inhibitor BIA 3-335 shows the atomic interactions between the important residues at the active site and the inhibitor. This is the first report of a three-dimensional structure determination of COMT complexed with a potent, reversible, and tight-binding inhibitor that is expected to have therapeutic applications.

About this Structure

1H1D is a Single protein structure of sequence from Rattus norvegicus with , and as ligands. Active as Catechol O-methyltransferase, with EC number 2.1.1.6 Known structural/functional Site: . Full crystallographic information is available from OCA.

Reference

Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application., Bonifacio MJ, Archer M, Rodrigues ML, Matias PM, Learmonth DA, Carrondo MA, Soares-Da-Silva P, Mol Pharmacol. 2002 Oct;62(4):795-805. PMID:12237326

Page seeded by OCA on Thu Feb 21 12:56:17 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools